Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Receives $31.33 Consensus PT from Analysts

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) has earned an average rating of “Moderate Buy” from the nine research firms that are currently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating and seven have issued a buy rating on the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $31.3333.

Several equities research analysts recently issued reports on the company. Jefferies Financial Group reiterated a “buy” rating and issued a $31.00 price objective on shares of Monte Rosa Therapeutics in a report on Wednesday, January 7th. Weiss Ratings restated a “sell (d)” rating on shares of Monte Rosa Therapeutics in a report on Monday, December 29th. Zacks Research lowered shares of Monte Rosa Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, February 4th. Wedbush reissued an “outperform” rating and issued a $37.00 price target on shares of Monte Rosa Therapeutics in a research report on Wednesday, January 7th. Finally, Wells Fargo & Company upped their price objective on Monte Rosa Therapeutics from $22.00 to $30.00 and gave the stock an “overweight” rating in a research report on Thursday, January 8th.

Monte Rosa Therapeutics Stock Performance

Monte Rosa Therapeutics stock opened at $18.96 on Thursday. The company has a market capitalization of $1.23 billion, a PE ratio of 59.25 and a beta of 1.61. Monte Rosa Therapeutics has a fifty-two week low of $3.50 and a fifty-two week high of $25.77. The firm has a 50 day moving average price of $19.49 and a 200 day moving average price of $12.46.

Insider Buying and Selling

In other Monte Rosa Therapeutics news, CEO Markus Warmuth sold 5,466 shares of the company’s stock in a transaction dated Wednesday, January 7th. The stock was sold at an average price of $23.49, for a total transaction of $128,396.34. Following the sale, the chief executive officer owned 618,937 shares in the company, valued at $14,538,830.13. This represents a 0.88% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 6.90% of the stock is owned by insiders.

Hedge Funds Weigh In On Monte Rosa Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. raised its holdings in Monte Rosa Therapeutics by 8.6% in the fourth quarter. Vanguard Group Inc. now owns 3,246,500 shares of the company’s stock valued at $50,905,000 after acquiring an additional 257,547 shares in the last quarter. AQR Capital Management LLC lifted its position in shares of Monte Rosa Therapeutics by 459.4% during the 2nd quarter. AQR Capital Management LLC now owns 1,283,942 shares of the company’s stock worth $5,791,000 after purchasing an additional 1,054,406 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of Monte Rosa Therapeutics by 4.6% during the fourth quarter. Geode Capital Management LLC now owns 1,204,844 shares of the company’s stock worth $18,896,000 after purchasing an additional 53,278 shares in the last quarter. Marshall Wace LLP increased its holdings in Monte Rosa Therapeutics by 102.4% in the third quarter. Marshall Wace LLP now owns 902,834 shares of the company’s stock valued at $6,690,000 after buying an additional 456,754 shares during the last quarter. Finally, Vestal Point Capital LP acquired a new stake in Monte Rosa Therapeutics in the third quarter valued at $5,928,000. 79.96% of the stock is owned by institutional investors and hedge funds.

Monte Rosa Therapeutics Company Profile

Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.

The company’s main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience.